On­colyt­ic play­er abrupt­ly ter­mi­nates CMO, on­ly a year in, and elim­i­nates the job

A lit­tle more than a year af­ter Replimune CEO Philip Ast­ley-Sparke re­cruit­ed An­drea Pirzkall from BeiGene to run the de­vel­op­ment pro­grams for its on­colyt­ic im­muno-gene ther­a­py can­cer treat­ments, he’s now abrupt­ly show­ing her out.

The ex­pe­ri­enced drug de­vel­op­er was ter­mi­nat­ed “with­out cause,” the biotech dis­closed in an SEC fil­ing. The move, which hap­pened Wednes­day, in­clud­ed a de­ci­sion to elim­i­nate the CMO job and put her re­spon­si­bil­i­ties in the hands of the R&D chief.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER